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ABSTRACT  
Background 
Most guidelines recommend that patients who have undergone curative resection for primary 
colorectal cancer are followed up for 5 years with regular blood CEA tests to trigger further 
investigation for recurrence. With this single test approach, recurrence may be missed or patients 
may have false alarms. 
 
Methods 
The diagnostic accuracy of trends in CEA measurements for recurrent colorectal cancer, taken as 
part of the FACS (Follow-up After Colorectal Surgery) trial (2003-2014), were analysed. Investigation 
to detect recurrence was triggered by clinical symptoms, scheduled CT or colonoscopy, or a 
CEA>7µg/L above baseline. Time-dependent ROC analysis compared the diagnostic accuracy of CEA 
trends to single test results. CEA trends were estimated via linear regression.   
 
Results 
The area under the ROC curves (AUC) for CEA trend was consistently over 0.82 across all 5 years of 
follow-up. In comparison, the AUCs for single measurements ranged from 0.62 – 0.75. Improvement 
was most marked at the end of the first year of follow-up, with the AUC increasing from 0.62 (95% 
CI: 0.51-0.74) to 0.88 (95% CI: 0.81-0.95). However, no individual trend threshold achieved a 
sensitivity above 70% (30% missed cases). 
 
Conclusions  
Interpreting trends in CEA measurements instead of single CEA test results improves diagnostic 
accuracy for recurrence, but not sufficiently to warrant it being used as a single surveillance strategy 
to trigger further investigation. In the absence of a more accurate biomarker, monitoring trends in 
CEA should be combined with clinical, endoscopic, and imaging surveillance for improved accuracy. 
 
Key Words 
Carcinoembryonic antigen, ROC curve, serial measurements, colorectal cancer, recurrence 
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INTRODUCTION 
After initial treatment for colorectal cancer, most clinicians in Europe and North America follow-up 
patients to detect asymptomatic recurrence. Guidelines recommend using more than one diagnostic 
modality (1-5), and most clinicians employ a combination of clinical examination, carcinoembryonic 
antigen (CEA) testing, some imaging (usually CT-CAP), and colonoscopy to detect intra-luminal 
recurrence.  
 
Two recent trials, FACS (Follow-up After Colorectal Surgery) and CEA Watch, have confirmed that 
including CEA testing as part of follow-up advances diagnosis, more than doubling the number of 
recurrences that can be treated surgically with curative intent (6, 7). However, both trials suggest 
that the common approach to testing recommended by guidelines (acting on the results of single 
tests) is sub-optimal. In the FACS trial, recurrences were missed in patients who had experienced a 
gradual CEA rise and we previously suggested that this might be avoided by considering the trend in 
a series of results over time(8). In the CEA Watch trial, further investigation was based on CEA trend 
on the basis of evidence from other studies that it provide better diagnostic yields than a single test 
(9-14). 
 
Critics of intensive follow-up regimes point to the lack of evidence that pre-symptomatic diagnosis of 
recurrence improves survival. It is therefore important that the chosen follow-up regime does not 
cause harm and that it is cost-effective. A potential problem with acting on single raised CEA test 
results is that it can cause false alarms (leading to unnecessary CT scans). We therefore report here 
an observational analysis of CEA data from the FACS randomised controlled trial to quantify the 
advantage of making clinical decisions on the basis of CEA trend rather than the results of a single 
test, looking at the potential to avoid both missed cases of recurrence and of false alarms.  
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METHODS 
Secondary observational analysis of data from the FACS trial, a 2x2 pragmatic randomised factorial 
controlled trial comparing minimum post-surgery follow-up of colorectal cancer patients for 5 years 
with 3-6 monthly blood tests for carcinoembryonic antigen (CEA) and 6-12 monthly computerised 
tomography (CT) imaging (6) (see Appendix Tables A1 and A2 for exact testing schedule). Patients 
were recruited between 2003 and 2009 from 39 NHS hospitals across England who had undergone 
curative surgery for primary colorectal cancer and, after extensive testing (histology, imaging and a 
CEA ≤ 10µg/L), were confirmed to have no residual disease. The CEA analysis was undertaken using a 
Siemens Centaur XP analyser at a single laboratory with a standard quality control regime to ensure 
longitudinal stability. If the blood CEA level was 7µg/L or more above the patient’s baseline level 
(which was measured on entry to the trial) after repeat measurement, the GP was asked to refer the 
patient urgently to the local hospital for further investigation.  
The reference standard in the study was clinical diagnosis of colorectal cancer recurrence as 
determined by the multi-disciplinary team (MDT) at each hospital centre. As this was a pragmatic 
clinical trial in an NHS setting, all available evidence (which will have varied between hospitals and 
individual patients) was used to determine a diagnosis of recurrence, including imaging and biopsy 
results. All participant centres were bowel cancer specialist centres with diagnostic experience and 
expertise. Investigation for suspected recurrence could be triggered as a result of abnormal results 
on per-protocol colonoscopy or CT imaging, a CEA>7µg/L above their personal baseline, or 
suspicious symptoms. 
Linear regression was applied to capture the trend in individuals’ CEA measurements. The beta 
coefficient from each model was extracted and compared to using a threshold to interpret single 
CEA measurements. A selected value was used for the single measurement analysis. The CEA 
measurement at the time of diagnosing recurrence is often selected for analysis
(15)
. But this may 
overestimate the accuracy as in clinical practice all measurements are interpreted prospectively. We 
therefore looked across all measurements for each individual and identified, based on all possible 
thresholds, whether their measurements had risen above the threshold at any time point. Time-
dependent ROC analysis was utilised to demonstrate the trade-off between sensitivity and sensitivity 
when clinical decisions are based on different degrees of trend and area under the curves. All 
analyses were carried out using the statistical package R (http://www.R-project.org/); the 
dependent ROC analysis was carried using the R package timeROC (16).  
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RESULTS 
Table 1 presents the clinical characteristics of the patients included in the analysis. The median 
number of CEA measurements available for each participant was 13 (IQR: 10-14), with a median of 6 
(IQR: 3–9) measurements in patients who developed a recurrence and 14 (IQR: 13-14) for those who 
did not develop a recurrence. In this analysis, we included all individuals who had at least two CEA 
measurements available, but this means that individuals that have a recurrence detected in the first 
three months had to be excluded. The analysis was based on 582 of the 602 patients allocated to the 
two arms of the study who received CEA testing (see flow-chart and reasons for exclusions in 
Appendix Figure A1). 
Of the 96/104 patients with recurrence who had undergone at least two CEA tests, 6 had a falling 
level, 6 had an initial fall before a rise, 13 had stable levels, and 23 had a rising CEA level that did not 
exceed the 5µg/L threshold. Even among the 52 patients whose CEA did rise above 5µg/L, it took a 
median of 15.9 months (IQR: 6.8 – 29.9) to go above the threshold. Of the 478 patients without 
recurrence, 15 (3%) had two or more raised CEA measurements above 5µg/L within the study 
period. These false alarms occurred in 12% of smokers and 3% of non-smokers (OR=4.43, 95% CI: 
1.34-14.7, p=0.01). Smokers should therefore be informed of the false-alarm risk and be followed up 
with a different modality, such as CT-CAP. 
INSERT FIGURE 1 HERE 
Figure 1 compares the CEA trend in patients with and without recurrence. CEA levels tended to be 
very stable in patients free of recurrence but those from patients with disease recurrence had 
variable trends with a 100 fold standard deviation. 
INSERT FIGURE 2 HERE 
Figure 2 compares the time-dependent ROC curves at Year 1 for making the decision to investigate 
on the basis of the trend compared to single measurements. The table shows that across all years of 
follow-up, the AUC for CEA trend remains over 0.80. The time-dependent AUC estimates for the 
trend analysis are consistently higher than the single measurement interpretation (although in some 
cases the 95% confidence intervals overlap). This appeared to be constrained to a maximum 
sensitivity of 70% without losing substantial test specificity. Making decisions on CEA would not 
allow CEA alone to be used as a triage test because even at the point of optimal trade-off between 
sensitivity and specificity, 3 in 10 recurrences would be missed. Additional tests to maintain 
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sensitivity should be carried out as per local protocol. For details of additional testing and associated 
timings within the FACS trial, please refer to Tables A1 and A2 in the Appendix. 
The time-dependent ROC analysis allowed us to explore optimal thresholds for interpreting trend 
(change/yr). These were: Year 1 1.7ug/L; Year 2 1.4ug/L; Year 3 0.8ug/L; Year 4 0.5 ug/L; Year 5 0.3 
ug/L.  
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DISCUSSION 
Although debate continues about the benefits of surveillance (17), most clinicians continue to 
monitor CEA in addition to CT scans at intervals with the aim of detecting pre-symptomatic 
recurrence. Our results suggest that the diagnostic accuracy of CEA trends is better than interpreting 
the result of a single test, but a substantial number of recurrences still would be missed if CEA was 
utilised as a single surveillance method.   
In the absence of alternative markers, we can make some suggestions for an improved CEA 
monitoring schedule based on the FACS data. As per the FACS protocol, 3 monthly measurements in 
year 2 of follow-up and 6 monthly measurements for the remaining time were sufficient to monitor 
trend. As almost half the recurrences were identified during the first year of follow-up however, we 
would suggest a CEA monitoring schedule that consists of monthly measurements in the first 3 
months and 2-monthly for the remainder of the first year. This would ensure that enough 
measurements are taken to observe a trend early on in follow-up (2 months onwards). In the first 
couple of months, single test measurements would still have to be interpreted. Based on the FACS 
data, a threshold of 10 ug/L was optimal. Possible thresholds for interpreting trend (change/yr) are 
reported in the results section, although these require further validation before implementing in 
clinical practice. To facilitate interpretation, laboratories could report trend over time as well as the 
absolute CEA level on their report forms.  
The cost-effectiveness and feasibility of such an intensive testing schedule would need to be fully 
evaluated though. The mean direct NHS cost of CEA testing in the FACS trial was estimated as 
£7.50/test so the cost of the additional 4 tests in year 1 would be approximately £30 (not taking 
account of subsequent price inflation) (18). A recent study in the Netherlands, the CEAwatch trial, 
compared an intensive follow-up protocol that included more frequent CEA measurements (bi-
monthly), but fewer outpatient visits, detecting more curable recurrences compared to standard 
practice(19). An economic evaluation of the trial, which included direct medical costs, productivity 
losses and travel expenses, was conducted and the ICER (incremental cost-effectiveness ratio) per 
curable recurrence was calculated. It was found that an additional $60,700 (€51,465) is needed to 
detect one additional patient with curable recurrent disease. Although the authors considered this 
to be acceptably low (19), until the quality of life and survival benefit of detecting pre-symptomatic 
recurrence is known, definitive conclusions are not possible (18). 
The main strengths of the FACS trial are that the analysis was undertaken on well-staged patients 
with robust outcome data. The CEA testing was centrally managed with good compliance, and all 
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analyses were done in one laboratory. The main limitation is that we do not have a reference 
standard at all time points. The precise time when a recurrence would have been detectable by a 
trend based analysis is not known. However, the length of follow-up and within-trial surveillance 
means missed recurrences were not likely. There may have existed a work-up bias as patients with a 
CEA>7µg/L above their personal baseline were referred for further investigation; however this 
selected threshold (2002) is higher than current guidelines. 
Due to the small number of recurrences it is not possible to use the present analysis to develop a 
definitive model and cut-off values that clinicians could use now to interpretation of trend. Ideally 
this would explore other factors that may bring granularity to the interpretation of individual trends 
(e.g. smoking status, tumour site and stage). 
Here we demonstrate that interpreting trends in CEA rather than single tests provides improved 
diagnostic accuracy. However, CEA is not sufficiently accurate as a single surveillance method and 
alternative markers are needed.  
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APPENDIX 
Table A1 Testing schedule in the FACS trial for the CEA & CT arm included in this analysis 
 Month of Follow-up 
Test 3 6 9 12 15 18 21 24 30 36 42 48 54 60 
CEA x x x x x x x x x x x x x x 
CT CAP  x  x  x  x x x x x x x 
OPA Review  x  x  x  x  x  x  x 
Colonoscopy              x 
 
Table A2 Testing schedule in the FACS trial for the CEA only arm included in this analysis 
 Month of Follow-up 
Test 3 6 9 12 15 18 21 24 30 36 42 48 54 60 
CEA x x x x x x x x x x x x x X 
CT CAP     x          
OPA Review  x  x  x  x  x  x  X 
Colonoscopy        x      x 
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Figure A1 Flow-chart of patients allocated to CEA testing within the FACS cohort to show origin of 
the data analysed here 
 
  
 
Randomised to CEA-
only arm 
(n=300) 
Randomised to 
CEA&CT arm 
(n=302) 
Recruits 
(n=602) 
Exclusions (n=20) 
 Postoperative deaths (n=10) 
 Withdrawn (n=9) 
 Lost to follow up (n=1) 
Followed up 
(n=582) 
Non-recurrence  
(n=478) 
Recurrence 
(n=104) 
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